As the first advanced therapy approved for atopic dermatitis, dupilumab offers an efficacious option for moderate to severe disease. Dr Amy Paller offers insights on how this biologic can help pediatric patients with eczema and their...
As the first advanced therapy approved for atopic dermatitis, dupilumab offers an efficacious option for moderate to severe disease. Dr Amy Paller offers insights on how this biologic can help pediatric patients with eczema and their...
In this interview, Dr Juul van den Reek discusses her commentary titled, “Data-driven Prediction of Biologic Treatment Responses in Psoriasis: Steps Towards Precision Medicine,” looking at a study conducted by Geifman et al.
In this interview, Dr Juul van den Reek discusses her commentary titled, “Data-driven Prediction of Biologic Treatment Responses in Psoriasis: Steps Towards Precision Medicine,” looking at a study conducted by Geifman et al.
New data presented at the AAD annual meeting show patients vaccinated for COVID-19 with pre-existing atopic dermatitis (AD) were not found to be at a greater risk of adverse events compared to patients without AD.
New data presented at the AAD annual meeting show patients vaccinated for COVID-19 with pre-existing atopic dermatitis (AD) were not found to be at a greater risk of adverse events compared to patients without AD.
Increased awareness of the nuances of diagnosing and treating patients with skin of color can improve training and research and help inform management.
Increased awareness of the nuances of diagnosing and treating patients with skin of color can improve training and research and help inform management.
Researchers aimed to evaluate cardiovascular risk in Slovak patients with psoriasis and investigate the relationship between cardiovascular risk and psoriasis features.
Researchers aimed to evaluate cardiovascular risk in Slovak patients with psoriasis and investigate the relationship between cardiovascular risk and psoriasis features.
Researchers aimed to evaluate serum levels of inflammatory cytokines, specifically tumor necrosis factor-alpha and IL-17, in patients with nail psoriasis.
Researchers aimed to evaluate serum levels of inflammatory cytokines, specifically tumor necrosis factor-alpha and IL-17, in patients with nail psoriasis.
